This winter, bronchiolitis, covid and flu had a lesser impact than in 2022-2023. The three acute respiratory infections caused less damage than last year.
The bronchiolaitis "vaccine" (Beyfortus) may be responsible for this improvement. Some 250,000 infants have received this treatment in France, one of four countries, such as the United States and Spain, to have used it so far. The authorities are already in discussions with Sanofi on ordering doses for fall-winter 2024-2025.